AUTHOR INDEX

(P = proceedings)

ABRAMS, S.M.L. *see* JOHNSTON, A.
AHRENSTEDT, Ö. *see* LENNERNÄS, H.
AJAYI, A.A., HORN, E. H., COOPER, J. & RUBIN, P. C. Effect of unfractionated heparin and the low molecular weight heparins, dalteparin and enoxaparin on platelet behaviour in pregnancy, 90P
AKIYAMA, H. *see* UEMATSU, T.
ALDIGIER, J. C. *see* BEVAN, E. G.
ALVÁN, G. *see* PAINTAUD, G.
ANDERSON, P. J., WALKER, R., TOMLINSON, B. & CRITCHLEY, J. A. J. H. Acute haemodynamic effects of cilazapril in normotensive Chinese and Caucasians, 66P
ANDERSSON, A. *see* WALLÉN, N. H.
ANDERSSON, T. *see* BLOHME, I.
ANKIER, S. I. *see* MURDOCH, D. L.
AQUILONIUS, S.-M. *see* LENNERNÄS, H.
ARANKO, K. *see* MATTILA, M. J.
ARCHER, C. B. *see* KAVANAGH, G. M.
ARNAU, J. M. *see* RODRIGUEZ, C.
ARNOLD, I. R., MISTRY, R. J. & BARNETT, D. B. Comparison of the effects of chronic therapy with xamoterol and atenolol on human cardiac β-adrenoceptor density and coupling to adenylate cyclase, 70P
ASHGAR, J. *see* MURDOCH, D. L.
ASQUITH, P. A. *see* MARRIOTT, J. F.
AUTRET, E. *see* DUTERTRE, J. P.

BABER, N. S. *see* MACKAY, J.
BACH, G. L. *see* GEISSLINGER, G.
BANCROFT, A. *see* BELCH, J. J. F.
BARKER, J. E., MCLEOD, J. D., MASCARO, J. G., TREASURE, T. & PIPER, P. J. Effect of endothelial integrity and surgical preparation on responses of human saphenous vein to angiotensin II, 538P
BARLOW, R. *see* BARR, R. M.
BARNES, P. J. *see* MIURA, M.
BARNETT, D. B. *see* ARNOLD, I. R.
BARR, R. M., LAWLOR, F., JUDGE, M. R., COURTNEY, P., BARLOW, R., KOBZA BLACK, A., MALLET, A. I. & GREAVES, M. W. Platelet activating factor, lyso-platelet activating factor and arachidonic acid release in normal human skin and the influence of topical steroid treatment, 637
BARROW, S. E., DOKTOR, H. S., STRATTON, P. D., EDWARDS, J. S., HENRY, J. A., GOULD, S. & RITTER, J. M. Acute effects of ridogrel in patients with mild essential hypertension, 541P
BARTON, C. *see* HYMNA-TAYLOR, P.
BATEMAN, N. T. *see* THOMAS, S. H. L.
BECK, O. *see* SEIDEMAN, P.
BEERAHEE, A., TAYLOR, A. C., KAYE, C. M., DIERDORF, H. D. & ECKL, K. Pharmacokinetic profile of levcromakalim, a novel antihypertensive agent, following intravenous administration in healthy male volunteers, 81P
BELCH, J. J. F., MCCLAREN, M., LAU, C. S., MACKAY, I. R., BANCROFT, A., MCEWEN, J. & THOMPSON, J. M. Cicaprost, an orally active prostacyclin analogue: its effects on platelet aggregation and skin blood flow in normal volunteers, 643
BELK, D. *see* NOTARIANNI, L. J.
BELL, N. *see* NUGENT, A. M.
BELVISI, M. G. *see* MIURA, M.
BENNETT, P. N. *see* NOTARIANNI, L. J.
BERCKMANS, R. J. *see* GIANESE, F.
BERGSTRAND, R. *see* ERIKSSON, M.
BERTI, C. *see* JOHNSTON, A.
BEVAN, E. G., CHEE, L. C., MCGHEE, S. M. & MCINNES, G. T. Patients' attitude to participation in clinical trials, 204
BEVAN, E. G., CURRIE, E. M., MCGHEE, S. M. & MCINNES, G. T. Patient knowledge about diuretic prescription, 152
BEVAN, E. G., MCINNES, G. T., ALDIGIER, J. C., CONTE, J. J., GRUNFELD, J. P., HARPER, S. J., MEYER, B. H., PAULY, N. & WILKINSON, R. Effect of renal function on the pharmacokinetics and pharmacodynamics of trandolapril, 128
BILLAUD, E. M. *see* DUTERTRE, J. P.
BINNS, L. A. *see* COCKCROFT, J. R.
BIRMINGHAM, A. T. *see* GREAVES, J. L.
BIRMINGHAM, A. T. *see* JAMES, M. J.
BLACKWELL, C. P. *see* MACKAY, J.
BLAKE, D. R. *see* NAZHAT, N. B.
BLAKE, J. C., PALMER, J. L., MINTON, N. A. & BURROUGHS, A. K. The pharmacokinetics of intravenous ondansetron in patients with hepatic impairment, 441
BLAUW, G. J. *see* BRUNING, T. A.
BLOCK, G. A. *see* ECKERNAS, S.-A.
BLOHMÉ, I., IDSTROM, J.-P. & ANDERSSON, T. A study of the interaction between omeprazole and cyclosporine in renal transplant patients, 156
BLOT, PH. *see* LUPOGLAZOFF, J. M.
BLOUIN, R., CHAUDHARY, I., NISHIHARA, K. & COX, S. The effects of liver and renal disease on stereoselective serum binding of flurbiprofen, 62
BOELAERT, J. *see* MOVIN-OSSWALD, G.
BORGHOLST, O. *see* DAHLOF, B.
BOULOUX, P.-M. G. *see* MUNROE, P. B.
BOWES, S. G. *see* CHARLETT, A.
BOWES, S. G. *see* WELLER, C.
BOYD, S. *see* SILKE, B.
BRANDENBURG, H. C. *see* COHEN, A. F.
BRECKENRIDGE, A. *see* WALLEY, T.
BRECKENRIDGE, A. M. *see* HELSBY, N. A.
BREIMER, D. D. *see* COHEN, A. F.
BREIMER, D. D. *see* STEVENINCK VAN, A. L.
BREIMER, D. D. *see* VAN ROOIJ, J.
BREIMER, D. D. *see* VAN STEVENINCK, A. L.
BRENNAN, G. M. *see* MCGRATH, L. T.
BRIËT, E. *see* KROON, C.
BROCKMEYER, N. H. *see* SPATZ, D.
BROCKMEYER, N. H., FRÜHAUF, S., TILLMANN, I., MERTINS, L., SPATZ, D. & GOOS, M. Does zidovudine affect endogenous interferon plasma concentrations and antipyrine elimination in different stages of HIV-1 infection, 534P
BRODDE, O.-E., DROEGE, A., HILLEMAN, S., KUNDE, K., SARIKOUCH, S. & ZERKOWSKI, H.-R. Is stimulation of cardiac β_2-adrenoceptors in end-stage heart failure of any clinical relevance? 71P
BRÖIJERSÉN, A. *see* WALLÉN, N. H.
BRØSEN, K. *see* GRAM, L. F.
BRØSEN, K. *see* SKJELBO, E.
BROWN, M. J. *see* FERRO, A.
BROWN, M. J. *see* SUN, B.
BRUNE, K. *see* GEISSLINGER, G.
BRUNING, T. A., CHANG, P. C., BLAUW, G. J., VERMEIJ, P. & VAN ZWIETEN, P. A. 5-HT induces vasodilation in the human forearm via the release of nitric oxide, 68P
BRUNO, R. *see* VAN ROOIJ, J.
BULLER, H. R. *see* GIANESE, F.
BUNNAG, D. *see* KARBWANG, J.
BURGGRAAF, J., SCHOEMAKER, H. C. & COHEN, A. F. Changes in portal blood flow after food intake measured with echo-Doppler, 548P

BÜRGI, M. *see* VAN MANDACH, U.
BURROUGHS, A. K. *see* BLAKE, J. C.
BURY, M., DINGEMANSE, J., GIESCHKE, R., ZELL, M., RONCARI, G. & VAN BRUMMELEN, P. Clinical pharmacodynamics and pharmacokinetics of a novel non-benzodiazepine hypnotic, 533P
BUSTO, U. *see* WU, D.
BYE, A. *see* CHEE, K. Y.
BYRON, D. *see* CHEE, K. Y.

CALVER, A. L., COLLIER, J. G. & VALLANCE, P. J. T. Effect of N^G-monomethyl-L-arginine (L-NMMA) on forearm blood flow (FBF) in treated hypertensive patients, 68P
CARNEIRO-SAMPAIO, M. M. S. *see* CONDINO-NETO, A.
CARVER, J. G. *see* CARVER, J. G.
CARVER, J. G., CARVER, J. G., GRAHAME-SMITH, D. G., STEWART JOHNSON, E. & MADGWICK, Z. The effects of 5-HT and *m*-chlorophenylpiperazine (m-CPP) on the efflux of [^{3}H]-5-HT from human perfused platelets, 473
CAULFIELD, M. *see* MUNROE, P. B.
CHADWICK, I. *see* HAQ, I.
CHAN, R., HEMERYCK, L., SABRA, K. & FEELY, J. Utilisation of formularies and the impact of providing 'free' BNF with specific advice to prescribers in a general hospital, 550P
CHANG, P. C. *see* BRUNING, T. A.
CHANTEPIE, A. *see* DUTERTRE, J. P.
CHAPPEY, O. *see* LUPOGLAZOFF, J. M.
CHARLES, B. G. *see* SIDHU, J. S.
CHARLETT, A. *see* WELLER, C.
CHARLETT, A., BOWES, S. G., O'NEILL, C. J. A., FRITH, C., DOBBS, S. M. & DOBBS, R. J. Bradyphrenia in idiopathic Parkinsonism: a nosological entity, partially reversible by exogenous substances, 84P
CHAUDHARY, I. *see* BLOUIN, R.
CHEE, K. Y., LEE, D., BYRON, D., NAIDOO, D. & BYE, A. A simple collection method for saliva in children: potential for home monitoring of carbamazepine therapy, 311
CHEE, L. C. *see* BEVAN, E. G.
CHOUDRY, N. B., STUDHAM, J., HARLAND, D. & FULLER, R. W. Modulation of capsaicin induced airway reflexes in humans: effect of monoamine oxidase inhibition, 184
CHOWIENCZYK, P. *see* COCKCROFT, J. R.
CHOWIENCZYK, P. J., COCKCROFT, J. R. & RITTER, J. M. Blood flow responses to brachial artery administration of acetylcholine depend on forearm length in man, 542P
CHOY, A.-M. J. *see* LANG, C. C.
CHOY, A. M. *see* LANG, C. C.
CLIFFORD, P., UNWIN, R. J., DOLLERY, C. T. & WILKINS, M. R. Assessment of α-adrenoceptor selectivity of bunazosin Retard in man, 541P
COCKCROFT, J. R. *see* CHOWIENCZYK, P. J.
COCKCROFT, J. R., BINNS, L. A., HOWES, A. J. & RITTER, J. M. Effect of racemic nebivolol on forearm blood flow in healthy volunteers, 542P
COCKCROFT, J. R., CHOWIENCZYK, P., ELLIOTT, T. G. & RITTER, J. M. Lack of effect of enalaprilat on the action of vasoactive intestinal polypeptide in the human forearm, 525
COHEN, A. F. *see* BURGGRAAF, J.
COHEN, A. F. *see* KROON, C.
COHEN, A. F. *see* VAN GRIENSVEN, J. M. T.
COHEN, A. F. *see* VAN ROOIJ, J.
COHEN, A. F. *see* VAN STEVENINCK, A. L.
COHEN, A. F. *see* WALLNOFER, A. E.
COHEN, A. F., KROON, R., SCHOEMAKER, H. C., BREIMER, D. D., VAN VLIET-VERBEEK, A. & BRANDENBURG, H. C. The bioavailability of digoxin from three oral formulations measured by a specific h.p.l.c. assay, 136
COLE, P. J. *see* TSANG, K. T.
COLES, S. J. *see* TSANG, K. T.
COLLART, L., LUTHY, C. & DAYER, P. Partial inhibition of tramadol antinociceptive effect by naloxone in man, 73P
COLLIER, J. G. *see* CALVER, A. L.
COLLINS, W. C. J. *see* FEELY, J.
CONDINO-NETO, A., MUSCARA, M. N., GRUMACH, A. S., CARNEIRO-SAMPAIO, M. M. S. & DE NUCCI, G. Neutrophils and mononuclear cells from patients with chronic granulomatous disease release nitric oxide, 485
CONNELL, J. M. C. *see* MORRIS, A. D.
CONTE, J. J. *see* BEVAN, E. G.
COOKE, E. D. *see* LI KAM WA, T. C.
COOPER, J. *see* AJAYI, A. A.
CORNISH, R. *see* FOWLER, G.
CORNISH, R. *see* WEBSTER, J.
COST, W. S. *see* VAN DER KLAUW, M. M.
COURTNEY, P. *see* BARR, R. M.
COUTIE, W. J. R. *see* NEWNHAM, D. M.
COX, S. *see* BLOUIN, R.
CRAIG, P. S. *see* WEN, H.
CRICHTON, W. A. *see* FOWLER, G.
CRICHTON, W. A. *see* WEBSTER, J.
CRITCHLEY, J. A. J. H. *see* ANDERSON, P. J.
CROME, P. *see* PECK, R. W.
CULLEN, M. *see* FEELY, J.
CURRAM, J. *see* HYMNA-TAYLOR, P.
CURRIE, E. M. *see* BEVAN, E. G.

DAHLÖF, B., GRUNDESTAM, J., BORGHOLST, O., LINDH, A., EKBLAD, G., ENGSTRAND, C., LARSSON, C., SCARTH, B. & LIDMAN, K. Antihypertensive effect and tolerability of the fixed combination of felodipine ER and metoprolol CR compared with individual components, 92P
DANIEL, H. *see* MUNROE, P. B.
DANISH UNIVERSITY ANTIDEPRESSANT GROUP *see* GRAM, L. F.
DAVIES, D. L. *see* MURDOCH, D. L.
DAVIES, H. A. *see* LENNARD, L.
DAVIES, R. H. & SHERIDAN, D. J. The treatment of heart failure—what next? 557
DAVIES, T. M. E. *see* KARBWANG, J.
DAVIES, T. M. E. *see* EDWARDS, G.
DAYER, P. *see* COLLART, L.
DE BOER, A. *see* KROON, C.
DE MEY, C. & ENTERLING, D. Disagreement between standard transthoracic impedance cardiography and the automated transthoracic electrical bioimpedance method in estimating the cardiovascular responses to phenylephrine and isoprenaline in healthy man, 349
DE NUCCI, G. *see* CONDINO-NETO, A.
DE SOUSA, G. *see* MARRE, F.
DE VRIES, T. P. G. M. Presenting clinical pharmacology and therapeutics: general introduction, 577
DE VRIES, T. P. G. M. Presenting clinical pharmacology and therapeutics: a problem based approach for choosing and prescribing drugs, 581
DE VRIES, T. P. G. M. Presenting clinical pharmacology and therapeutics: the course in pharmacotherapeutics, 587
DE VRIES, T. P. G. M. Presenting clinical pharmacology and therapeutics: evaluation of a problem based approach for choosing drug treatments, 591
DEL BIANCO, E. *see* GEPPETTI, P.
DENNISON, J. K. *see* LINK, C. G. G.
DICKINSON, R. G., KING, A. R., MCKINNON, G. E., HOOPER, W. D., EADIE, M. J. & HERKES, G. K. Studies on the renal excretion of the acyl glucuronide, phenolic glucuronide and sulphate conjugate of diflunisal, 609
DIERDORF, H. D. *see* BEERAHEE, A.
DINGEMANSE, J. *see* BURY, M.

DOBBS, R. J. *see* CHARLETT, A.
DOBBS, R. J. *see* WELLER, C.
DOBBS, S. M. *see* CHARLETT, A.
DOBBS, S. M. *see* WELLER, C.
DOKTOR, H. S. *see* BARROW, S. E.
DOLLERY, C. T. *see* CLIFFORD, P.
DONNELLY, R. *see* MORRIS, A. D.
DOROW, R. *see* DUKA, T.
DROEGE, A. *see* BRODDE, O.-E.
DUBINI, A. *see* JOHNSTON, A.
DUGGAN, C. *see* THOMAS, S. H. L.
DUKA, T., SCHUTT, B., KRAUSE, W., DOROW, R., MCDONALD, S. & FICHTE, K. Human studies on abecarnil, a new β-carboline anxiolytic: safety, tolerability and preliminary pharmacological profile, 386
DUTERTRE, J. P., BILLAUD, E. M., AUTRET, E., CHANTEPIE, A., OLIVER, I. & LAUGIER, J. Inhibition of angiotensin converting enzyme with enalapril maleate in infants with congestive heart failure, 528

EADIE, M. J. *see* DICKINSON, R. G.
EBNER, T. & EICHELBAUM, M. The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism, 426
ECKERNAS, S.-A., ROOS, B.-E., KVIDAL, P., ERIKSSON, L.-O., BLOCK, G., NEAFUS, R. P. & HAIGH, J. R. M. The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia, 284
ECKL, K. *see* BEERAHEE, A.
EDELMAN, K. *see* WILLIAMS, P. E. O.
EDWARDS, C. *see* KAMALI, F.
EDWARDS, G. *see* HELSBY, N. A.
EDWARDS, G., MCGRATH, C. S., WARD, S. A., SUPANARANOND, W., PUKRITTAYAKAMEE, S., DAVIES, T. M. E. & WHITE, N. J. Interactions among primaquine, malaria infection and other antimalarials in Thai subjects, 193
EDWARDS, J. S. *see* BARROW, S. E.
EICHELBAUM, M. *see* EBNER, T.
EKBLAD, G. *see* DAHLOF, B.
EKSBORG, S. *see* SEIDEMAN, P.
EL DEBANI, A. H. *see* FEELY, J.
ELBORN, J. S. *see* RILEY, M.
ELLIOTT, H. L. *see* MACFADYEN, R. J.
ELLIOTT, T. G. *see* COCKCROFT, J. R.
EMANUEL, M. B. *see* WOOD-BAKER, R.
ENGSTRAND, C. *see* DAHLOF, B.
ENTERLING, D. *see* DE MEY, C.
ERICSSON, Ö. *see* PAINTAUD, G.
ERIKSSON, L.-O. *see* ECKERNAS, S.-A.
ERIKSSON, M., LIDMAN, K. & BERGSTRAND, R. Plasma concentration *vs* time profiles of two different calcium-antagonist and β-adrenoceptor blocker fixed combinations, 77P
ERWIN, C. *see* RILEY, M.

FAGHER, B., LEIDHOLM, H., SJÖGREN, A. & MONTI, M. Effects of terbutaline on basal thermogenesis of human skeletal muscle and Na-K pump after 1 week of oral use—a placebo controlled comparison with propranolol, 629
FAIRLESS, A. J. *see* PRATT, S. K.
FAIRWEATHER, D. B., KERR, J. S., HILTON, S. & HINDMARCH, I. A placebo controlled double-blind evaluation of the pharmacodynamics of fengabine *vs* amitriptyline following single and multiple doses in elderly volunteers, 278
FEELY, J. *see* CHAN, R.
FEELY, J. *see* HALL, M.
FEELY, J. *see* MCCORMACK, P. M.
FEELY, J., COLLINS, W. C. J., CULLEN, M., EL DEBANI, A. H., MACWALTER, R. S., PEDEN, N. R. & STEVENSON, I. H. Potentiation of the hypoglycaemic response to glipizide in diabetic patients by histamine H_2-receptor anatagonists, 321
FERNER, R. E. *see* KAMALI, F.
FERRO, A., HALL, J. A. & BROWN, M. J. β_1-adrenoceptor blocker-induced β_2-adrenoceptor sensitisation is prevented by β_2-adrenoceptor blockade, 539P
FICHTE, K. *see* DUKA, T.
FOGARI, R., MALACCO, E., TETTAMANTI, F., GNEMMI, A. E. & MILANI, M. Evening *vs* morning isradipine sustained release in essential hypertension: a double-blind study with 24 h ambulatory monitoring, 51
FORD, G. A. Endothelial dependent venodilatory action of nebivolol in human hand veins, 537P
FORD, G. A., JAMES, O. F. W. & RAWLINS, M. D. Autonomic blockade in young and elderly healthy persons: haemodynamic responses and effect on cardiac β-adrenergic chronotropic responsiveness, 70P
FORD, J. M., TRUMAN, C. A., WILCOCK, G. K. & ROBERTS, C. J. C. Can blood concentrations of tacrine hydrochloride (THA) predict the risk of adverse effects? 82P
FORREST, G. *see* MURDOCH, D. L.
FOWLER, G. *see* LYONS, D.
FOWLER, G. *see* WEBSTER, J.
FOWLER, G., WEBSTER, J., LYONS, D., WITTE, K., CRICHTON, W. A., JEFFERS, T. A., WICKHAM, E. A., SANGHERA, S. S., CORNISH, R. & PETRIE, J. C. A comparison of amlodipine with elalapril in the treatment of moderate/severe hypertension, 491
FOWLES, S. E. *see* PRATT, S. K.
FREESTONE, S. *see* PRESCOTT, L. F.
FREESTONE, S., LI KAM WA, T. C. & LEE, M. R. The effect of the monoamine oxidase-B inhibitor selegiline on the metabolism of γ-L-glutamyl-L-dopa (gludopa) in man, 74P
FRIEDLANDER, Y. *see* JOHNSON, A. G.
FRITH, C. *see* CHARLETT, A.
FRÜHAUF, S. *see* BROCKMEYER, N. H.
FUHR, U., KLITTICH, K. & HORST STAIB, A. Inhibitory effect of grapefruit juice and its bitter principal, maringenin, on CYP1A2 dependent metabolism of caffeine in man, 431
FUHRMANN, G. *see* HINRICHSEN, H.
FULLER, R. W. *see* CHOUDRY, N. B.
FUSCO, B. M. *see* GEPPETTI, P.

GALTEAU, M. M. *see* MURA, C.
GEISSLINGER, G., STOCK, K. P., LOEW, D., BACH, G. L. & BRUNE, K. Variability in the stereoselective disposition of ibuprofen in patients with rheumatoid arthritis, 602
GEORGIOU, P. *see* PRATT, S. K.
GEPPETTI, P., TRAMONTANA, M., DEL BIANCO, E. & FUSCO, B. M. Capsaicin-desensitization to the human nasal mucosa selectively reduces pain evoked by citric acid, 178
GERARD, N. *see* MURA, C.
GERRARD, L., WHEELDON, N. M. & MCDEVITT, D. G. Central effects of combined bendrofluazide and atenolol administration, 552P
GIANESE, F., NURMOHAMED, M. T., IMBIMBO, B. P., BULLER, H. R., BERCKMANS, R. J. & TEN CATE, J. W. The pharmacokinetics and pharmacodynamics of dermatan sulphate MF701 during haemodialysis for chronic renal failure, 335
GIBB, D. *see* THOMAS, S. H. L.
GIESCHKE, R. *see* BURY, M.
GNEMMI, A. E. *see* FOGARI, R.
GOGGIN, T. *see* POWELL, J.
GOOS, M. *see* BROCKMEYER, N. H.
GOOS, M. *see* SPATZ, D.
GOULD, S. *see* BARROW, S. E.
GRAHAME-SMITH, D. G. *see* CARVER, J. G.
GRAM, L. F. *see* SKJELBO, E.

GRAM, L. F., BRØSEN, K. & THE DANISH UNIVERSITY ANTIDEPRESSANT GROUP. Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio, 649
GRAY, S. J. *see* ROLAN, P. E.
GREAVES, J. L., WILSON, C. G. & BIRMINGHAM, A. T. Assessment of the precorneal residence of an ophthalmic ointment in healthy subjects, 188
GREAVES, M. W. *see* BARR, R. M.
GREAVES, M. W. *see* KAVANAGH, G. M.
GREEN, *see* HARTLEY, R.
GROENHOUT, C. *see* MURDOCH, D. L.
GRUMACH, A. S. *see* CONDINO-NETO, A.
GRUNDESTAM, J. *see* DAHLOF, B.
GRUNFELD, J. P. *see* BEVAN, E. G.
GUELEN, P. J. M. *see* VREE, T. B.
GUY, S. *see* THAM, T. C. K.
GUY, S., HARRIS, C. M., JEFFERS, L. A., SILKE, B. & RIDDELL, J. G. Partial agonist activity of celiprolol assessed by echo-Doppler (ExerDop), 71P
GUYOT, B. *see* LUPOGLAZOFF, J. M.

HAFFNER, C. A., KENDALL, M. J., MAXWELL, S. & HUGHES, B. The lipolytic effect of β_1- and β_2-adrenoceptor activation in healthy volunteers, 35
HAIGH, J. R. M. *see* ECKERNAS, S.-A.
HALABI, A. *see* HINRICHSEN, H.
HALABI, A. & KIRCH, W. The effects of ibopamine on cardiac and renal function in patients with congestive heart failure and different degrees of renal function, 539P
HALL, I. P. Isoenzyme selective phosphodiesterase inhibitors: potential clinical uses, 1
HALL, J. A. *see* FERRO, A.
HALL, M. *see* MCCORMACK, P. M.
HALL, M., MCCORMACK, P. M. E. & FEELY, J. Requirements for an educational poster to aid drug recognition, 549P
HALLAK, H. O., WEDLUND, P. J., MODI, M. W., PATEL, I. H., LEWIS, G. L., WOODRUFF, B. & TROWBRIDGE, A. A. High clearance of (S)-warfarin in a warfarin-resistant subject, 327
HAMMARLUND-UDENAES, M. *see* MOVIN-OSSWALD, G.
HAQ, I., LENNARD, M. S., CHADWICK, I., YEO, W. W., JACKSON, P. R., RAMSAY, L. E. & TUCKER, G. T. Does irreversible inhibition of CYP2D6 by propranolol result in phenocopying? 73P
HARLAND, D. *see* CHOUDRY, N. B.
HARPER, S. J. *see* BEVAN, E. G.
HARRINGTON, C. *see* THOMAS, S. H. L.
HARRIS, C. M. *see* GUY, S.
HARRIS, C. M. *see* JASSAL, V.
HARTLEY, R., QUINN, M., GREEN, M. & LEVENE, M. I. Morphine glucuronidation in premature neonates, 314
HAYES, J. R. *see* MCGRATH, L. T.
HEALY, D. P. *see* SAHAI, J.
HECKENBERGER, R. *see* VILLANUEVA, M.
HELSBY, N. A., EDWARDS, G., BRECKENRIDGE, A. M. & WARD, S. A. The multiple dose pharmacokinetics of proguanil, 656
HEMERYCK, L. *see* CHAN, R.
HENDERSON, I. S. *see* LANG, C. C.
HENRY, J. A. *see* BARROW, S. E.
HERINGS, R. M. C. *see* VAN DER KLAUW, M. M.
HERITY, N. *see* THAM, T. C. K.
HERKES, G. K. *see* DICKINSON, R. G.
HIGGINS, K. S. *see* YEO, W. W.
HILL, S. J. *see* JAMES, M. J.
HILLEMAN, S. *see* BRODDE, O.-E.
HILTON, S. *see* FAIRWEATHER, D. B.
HINDMARCH, I. *see* FAIRWEATHER, D. B.
HINRICHSEN, H., HALABI, A. & KIRCH, W. Autonomic blockade and cardiovascular effects of various H_2-receptor antagonists, 543P
HINRICHSEN, H., HALABI, A., FUHRMANN, G. & KIRCH, W. Dose-dependent heart rate reducing effect of nizatidine, a histamine H_2-receptor antagonist, 461
HJEMDAHL, P. *see* WALLÉN, N. H.
HOOKER, M. *see* WILLIAMS, P. E. O.
HOOPER, W. D. *see* DICKINSON, R. G.
HORN, E. H. *see* AJAYI, A. A.
HORST STAIB, A. *see* FUHR, U.
HOWARTH, P. H. *see* WOOD-BAKER, R.
HOWES, A. J. *see* COCKCROFT, J. R.
HOWLAND, K. *see* MURDOCH, R. D.
HUCH, A. *see* VAN MANDACH, U.
HUGHES, A. D. *see* SUNMAN, W.
HUGHES, B. *see* HAFFNER, C. A.
HUTCHINSON, K. *see* WOOD-BAKER, R.
HUUPPONEN, R. *see* LAHDES, K.
HYMNA-TAYLOR, P., BARTON, C., CURRAM, J. & RUBIN, P. The influences of the 'Spansule' sustained release mechanism on the bioavailability of nifedipine at steady state, 76P

IDSTRÖM, J.-P. *see* BLOHME, I.
IMBIMBO, B. P. *see* GIANESE, F.
INABA, T. *see* WU, D.
INGRAM, J. *see* ROLAN, P. E.
INGWERSEN, S. H., MANT, T. G. K. & LARSEN, J. J. Food intake increases the relative oral bioavailability of vanoxerine, 308

JACKSON, P. R. *see* HAQ, I.
JACKSON, P. R. *see* YEO, W. W.
JACKSON, S. H. D. *see* PECK, R. W.
JACQZ-AIGRAIN, E. *see* LUPOGLAZOFF, J. M.
JACQZ-AIGRAIN, E. *see* MURA, C.
JAMES, M. J., BIRMINGHAM, A. T. & HILL, S. J. Partial mediation by nitric oxide of the relaxation of human isolated detrusor strips in response to electrical field stimulation, 366
JAMES, O. F. W. *see* FORD, G. A.
JASSAL, V. HARRIS, C. M. & SILKE, B. Reproducibility of a new continuous echo-Doppler method (ExerDop) in man, 87P
JEFFERS, L. A. *see* GUY, S.
JEFFERS, T. A. *see* FOWLER, G.
JEFFERS, T. A. *see* WEBSTER, J.
JEFFERYS, D. B. *see* RAWLINS, M. D.
JOHANSSON, P. *see* NYBERG, G.
JOHNSON, A. G., SIMONS, L. A., SIMONS, J., FRIEDLANDER, Y. & MCCALLUM, J. Non-steroidal anti-inflammatory drugs and hypertension in the elderly: a community-based cross-sectional study, 455
JOHNSTON, A., ABRAMS, S. M. L., PATEL, M., SHAH, G., BERTI, C., DUBINI, A., STROLIN-BENEDETTI, M. & TURNER, P. Bioequivalence of controlled release nicergoline 60 mg once daily *vs* the plain form 30 mg twice daily in 24 male subjects, 80P
JOHNSTON, G. D. *see* MCGRATH, L. T.
JONES, A. W. Letter to the Editors. Back estimation of blood alcohol concentrations, 669
JONSSON, U. *see* NYBERG, G.
JUDGE, M. R. *see* BARR, R. M.

KAILA, T. & MARTTILA, R. Receptor occupancy in lumbar CSF as a measure of the antagonist activity of atenolol, metoprolol and propranolol in the CNS, 507
KAILA, T. *see* LAHDES, K.
KALOW, W. *see* WU, D.
KAMALI, F. Determination of diazepam and its metabolite desmethyldiazepam by solid phase extraction and reverse phase high performance liquid chromatography, 78P
KAMALI, F., EDWARDS, C., THOMAS, S. H. L. & RAWLINS, M. D. The effect of ciprofloxacin on diazepam pharmacokinetics, 78P
KAMALI, F., THOMAS, S. H. L. & FERNER, R. E. Paracetamol elimination in patients with non-

insulin dependent diabetes mellitus, 58
KARBWANG, J., DAVIES, T. M. E., LOOAREESUWAN, S., MOLUNTO, P., BUNNAG, D. & WHITE, N. J. A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males, 265
KARBWANG, J., THANAVIBUL, A., MOLUNTO, P. & NA BANGCHANG, K. The pharmacokinetics of quinine in patients with hepatitis, 444
KAVANAGH, G. M., GREAVES, M. W. & ARCHER, C. B. Intradermal effects of Rα-methylhistamine and thioperamide in human skin, 545P
KAYE, C. M. *see* BEERAHEE, A.
KEENE, O. N. *see* MACKAY, J.
KENDALL, M. J. *see* HAFFNER, C. A.
KERR, J. S. *see* FAIRWEATHER, D. B.
KHAN, M. M. *see* RILEY, M.
KING, A. R. *see* DICKINSON, R. G.
KING, D. J. *see* MANNION, M. F.
KIRCH, W. *see* HALABI, A.
KIRCH, W. *see* HINRICHSEN, H.
KIRCH, W., KLEINBLOESEM, C. & MESCHEDER, A. Dose dependence of a digoxin/calcium antagonist interaction, 535
KLEINBLOESEM, C. *see* KIRCH, W.
KLITTICH, K. *see* FUHR, U.
KLUFT, C. *see* WALLNOFER, A. E.
KNUTSON, L. *see* LENNERNÄS, H.
KOBZA BLACK, A. *see* BARR, R. M.
KOOISTRA, T. *see* WALLNOFER, A. E.
KORRAPATI, M. R. *see* LOI, C.-M.
KRAUSE, W. *see* DUKA, T.
KRISHNAMOORTHY, R. *see* MURA, C.
KROON, C., DE BOER, A., KROON, J. M., SCHOEMAKER, H. C., BRIET, E. & COHEN, A. F. Comparison of the bioavailability of heparin and low molecular weight heparin(oids) after subcutaneous administration in healthy volunteers, 535P
KROON, J. M. *see* KROON, C.
KROON, J. M. *see* VAN GRIENSVEN, J. M. T.
KROON, R. *see* COHEN, A. F.
KUITUNEN, T. *see* MATTILA, M. J.
KUNDE, K. *see* BRODDE, O.-E.
KVIDAL, P. *see* ECKERNAS, S.-A.

LACOURCIERE, Y., LEFEBVRE, J., PROVENCHER, P. & POIRIER, L. Comparison of quinapril and atenolol as single drugs or in combination with hydrochlorothiazide in moderate to severe hypertensives, using automated ambulatory monitoring, 121
LAHDES, K., HUUPPONEN, R., KAILA, T., MONTI, D., SAETTONE, M. F. & SALMINEN, L. Plasma concentrations and ocular effects of cyclopentolate after ocular application of three formulations, 479
LAMBERT, W. *see* WALLNOFER, A. E.
LANG, C. C. *see* STURROCK, N. D. C.
LANG, C. C., CHOY, A.-M. J., RAHMAN, A. R. & STRUTHERS, A. D. Renal effects of low dose prazosin in patients with congestive heart failure, 538P
LANG, C. C., CHOY, A. M., HENDERSON, I. S. & STRUTHERS, A. D. Atrial natriuretic factor may have a specific anti-cyclosporin A effect in man, 90P
LAPORTE, J. R. *see* RODRIGUEZ, C.
LAROCHE, J. *see* PRATT, S. K.
LARSEN, J. J. *see* INGWERSEN, S. H.
LARSSON, C. *see* DAHLOF, B.
LARSSON, P. T. *see* WALLÉN, N. H.
LAU, C. S. *see* BELCH, J. J. F.
LAUGIER, J. *see* DUTERTRE, J. P.
LAWLOR, F. *see* BARR, R. M.
LAWSON, M. *see* MUNROE, P. B.
LEAVENS, W. *see* ROLAN, P. E.
LECOMTE, J. M. *see* O'CONNOR, B. J.
LEE, D. *see* CHEE, K. Y.
LEE, D. R. *see* PECK, R. W.
LEE, M. R. *see* FREESTONE, S.
LEFEBVRE, J. *see* LACOURCIERE, Y.
LEIDHOLM, H. *see* FAGHER, B.
LEIGH, T. J. *see* LINK, C. G. G.
LEMKES, H. H. P. J. *see* VAN GRIENSVEN, J. M. T.
LENNARD, L., DAVIES, H. A. & LILLEYMAN, J. S. The pharmacokinetics of oral thioguanine in children with acute lymphoblastic leukaemia, 75P
LENNARD, M. S. *see* HAQ, I.
LENNARD, M. S. *see* SIMOOYA, O. O.
LENNERNÄS, H., NILSSON, D., AQUILONIUS, S.-M., AHRENSTEDT, O., KNUTSON, L. & PAALZOW, L. K. The effect of L-leucine on the absorption of levodopa, studied by regional jejunal perfusion in man, 243
LEVENE, M. I. *see* HARTLEY, R.
LEWIS, G. L. *see* HALLAK, H. O.
LI KAM WA, T. C. *see* FREESTONE, S.
LI KAM WA, T. C., COOKE, E. D. & TURNER, P. A comparison of the effects of captopril and enalapril on skin responses to intradermal bradykinin and skin blood flow in the human forearm, 8
LIDMAN, K. *see* DAHLOF, B.
LIDMAN, K. *see* ERIKSSON, M.
LIDMAN, K. *see* NYBERG, G.
LILLEYMAN, J. S. *see* LENNARD, L.
LINDH, A. *see* DAHLOF, B.
LINK, C. G. G., LEIGH, T. J. & DENNISON, J. K. The effects of BRL-46470A, a novel 5-HT_3 receptor antagonist, and lorazepam on psychometric performance and the EEG, 395
LIPWORTH, B. J. *see* NEWNHAM, D. M.
LIPWORTH, B. J. *see* WHEELDON, N. M.
LOEW, D. *see* GEISSLINGER, G.
LOI, C.-M., WEI, X., PARKER, B. M., KORRAPATI, M. R. & VESTAL, R. E. The effect of tocainide on theophylline metabolism, 437
LOOAREESUWAN, S. *see* KARBWANG, J.
LOPEZ-GIL, J. A. & VERE, D. W. Tricyclic drugs prolong threshold and tolerance times for electrical stimulation pain but propafenone prolongs only tolerance, 553P
LOWE, S. *see* RAY-CHAUDHURI, K.
LUPOGLAZOFF, J. M., JACQZ-AIGRAIN, E., GUYOT, B., CHAPPEY, O. & BLOT, PH. Endogenous digoxin-like immunoreactivity during pregnancy and at birth, 251
LUTHY, C. *see* COLLART, L.
LYNCH, G. *see* MANNION, M. F.
LYONS, D. *see* FOWLER, G.
LYONS, D. *see* WEBSTER, J.
LYONS, D., FOWLER, G., WEBSTER, J. & PETRIE, J. C. An assessment of the pharmacodynamic and pharmacokinetic interaction of lacidipine and atenolol in mild to moderate hypertension, 85P

MACFADYEN, R. J., ELLIOTT, H. L., MEREDITH, P. A. & REID, J. L. Haemodynamics and hormonal responses to oral enalapril in salt depleted normotensive man, 299
MACKAY, E. *see* WALLEY, T.
MACKAY, I. R. *see* BELCH, J. J. F.
MACKAY, J., WATSON, P., BLACKWELL, C. P., KEENE, O. N., BABER, N. S. & SEVER, P. S. Inhibition of precursor responses to intravenous angiotensin II by a specific AT_1-receptor antagonist, GR117289C, in healthy subjects, 88P
MACWALTER, R. S. *see* FEELY, J.
MADGWICK, Z. *see* CARVER, J. G.
MAILLOT, F. *see* ROLAN, P. E.
MALACCO, E. *see* FOGARI, R.
MALLET, A. I. *see* BARR, R. M.
MANNION, M. F., LYNCH, G. & KING, D. J. Absence of acute tolerance to the effects of promethazine on saccadic eye movements, 551P
MANT, T. G. K. *see* INGWERSEN, S. H.
MARRE, F., DE SOUSA, G., ORLOFF, A. M. & RAHMANI, R. Letter to the Editors. *In vitro* interaction

between cyclosporin A and macrolide antibiotics, 447
MARRIOTT, J. F., ASQUITH, P. A. & SHORROCK, C. J. The use of proprietary medicines by patients presenting with peptic ulcer haemorrhage, 451
MARTTILA, R. *see* KAILA, T.
MASCARO, J. G. *see* BARKER, J. E.
MATHIAS, C. J. *see* RAY-CHAUDHURI, K.
MATTILA, M. J. & VANAKOSKI, J. Oral single doses of erythromycin enhance the effects of midazolam on human performance, 77P
MATTILA, M. J., ARANKO, K. & KUITUNEN, T. Diazepam effects on the performance of healthy volunteers are not enhanced by treatment with the antihistamine ebastine, 272
MAULE, S. *see* RAY-CHAUDHURI, K.
MAWER, G. E. *see* WILDIN, J. D.
MAXWELL, S. *see* HAFFNER, C. A.
MCAUSLANE, J. A. N. *see* PRESCOTT, L. F.
MCCALLUM, J. *see* JOHNSON, A. G.
MCCLAREN, M. *see* BELCH, J. J. F.
MCCORMACK, K. J. Assessing transdermal delivery of topically applied NSAIDs under clinically relevant conditions, 544P
MCCORMACK, P. M., HALL, M. & FEELY, J. Adverse reactions to antihypertensive drugs: patient and doctor perspective, 536P
MCCORMACK, P. M. E. *see* HALL, M.
MCDEVITT, D. G. *see* GERRARD, L.
MCDEVITT, D. G. *see* WHEELDON, N. M.
MCDONALD, S. *see* DUKA, T.
MCDOWELL, I. *see* NUGENT, A. M.
MCEWEN, J. *see* BELCH, J. J. F.
MCFARLANE, L. C. *see* NEWNHAM, D. M.
MCFARLANE, L. C. *see* WHEELDON, N. M.
MCGAVOCK, H. A great thirst for knowledge, 217
MCGHEE, S. M. *see* BEVAN, E. G.
MCGRATH, C. S. *see* EDWARDS, G.
MCGRATH, L. T., BRENNAN, G. M., MCVEIGH, G. E., HAYES, J. R. & JOHNSTON, G. D. Effects of fish oil and olive supplements on HDL and VLDL concentrations in normotriglyceridaemic and hypertriglyceridaemia type 2 diabetic patients, 91P
MCINNES, G. T. *see* BEVAN, E. G.
MCINNES, G. T. *see* MURDOCH, D. L.
MCKINNON, G. E. *see* DICKINSON, R. G.
MCLAUGHLIN, A. *see* MURDOCH, D. L.
MCLEOD, J. D. *see* BARKER, J. E.
MCPARLAND, C. *see* SILKE, B.
MCVEIGH, G. E. *see* MCGRATH, L. T.
MEADE, T. W. *see* RODERICK, P. J.
MEIJER, P. *see* WALLNOFER, A. E.
MEREDITH, P. A. *see* MACFADYEN, R. J.
MERTINS, L. *see* BROCKMEYER, N. H.
MERTINS, L. *see* SPATZ, D.
MERZ, P. G. *see* WOODCOCK, B. G.
MESCHEDER, A. *see* KIRCH, W.
MEYER, B. H. *see* BEVAN, E. G.
MILANI, M. *see* FOGARI, R.
MINTON, N. A. *see* BLAKE, J. C.
MISTRY, R. J. *see* ARNOLD, I. R.
MITCHELL, H. W. *see* OMARI, T. I.
MIURA, M., BELVISI, M. G., WARD, J. K., TADJKARIMI, S., YACOUB, M. H. & BARNES, P. J. Bronchodilating effects of the novel potassium channel opener HOE 234 in human airways *in vitro*, 318
MODI, M. W. *see* HALLAK, H. O.
MOLUNTO, P. *see* KARBWANG, J.
MONTI, D. *see* LAHDES, K.
MONTI. M. *see* FAGHER, B.
MORELAND, T. A. *see* STEVENSON, I. H.
MORICE, A. H. *see* YEO, W. W.
MORRIS, A. D., DONNELLY, R., CONNELL, J. M. C. & REID, J. L. Metabolic effects of lacidipine: a placebo-controlled study using the euglycaemic hyperinsulinaemic clamp, 40
MOVIN-OSSWALD, G., BOELAERT, J., HAMMARLUND-UDENAES, M. & NILSSON, L. R. The pharmacokinetics of remoxipride and metabolites in patients with various degrees of renal function, 615
MUIRHEAD, G. J. *see* WILLIAMS, P. E. O.
MUNROE, P. B., CAULFIELD, M., DANIEL, H., LAWSON, M., BOULOUX, P.-M. G. & TURNER, P. Analysis of the insulin receptor RsaI polymorphism in essential hypertension, 540P
MURA, C., GERARD, N., VINCENT-VIRY, M., GALTEAU, M. M., JACQZ-AIGRAIN, E. & KRISHNAMOORTHY, R. Molecular heterogeneity of the XbaI defined 44kb allele of the CYP2D locus within the Caucasian population, 161
MURDOCH, D. L., ASHGAR, J., ANKIER, S. I., MCLAUGHLIN, A., GROENHOUT, C. & MCINNES, G. T. Influence of hepatic impairment on the pharmacokinetics of single doses of mirtazapine in elderly subjects, 76P
MURDOCH, D. L., FORREST, G., DAVIES, D. L. & MCINNES, G. T. A comparison of the potassium and magnesium sparing properties of amiloride and spironolactone in diuretic-treated normal subjects, 373
MURDOCH, R. D., YOULTEN, L. J. F., WILLIAMS, A. J. & HOWLAND, K. Plasma concentrations and urinary excretion of histamine after inhalation and subcutaneous injection of histamine, 171
MUSCARA, M. N. *see* CONDINO-NETO, A.

NA BANGCHANG, K. *see* KARBWANG, J.
NAIDOO, D. *see* CHEE, K. Y.
NAKANO, M. *see* UEMATSU, T.
NAKASHIMA, M. *see* OHTAWA, M.
NAKASHIMA, M. *see* UEMATSU, T.
NAZHAT, N. B., SINGH, D., SAHINOGLU, T. & BLAKE, D. R. Drug assay using electron spin resonance spectroscopy: a novel technique, 79P
NEAFUS, R. P. *see* ECKERNAS, S.-A.
NEELY, D. *see* NUGENT, A. M.
NEW, R. R. C. *see* WEN, H.
NEWNHAM, D. M., COUTIE, W. J. R., MCFARLANE, L. C. & LIPWORTH, B. J. Comparison of *in vitro* parameters of lymphocyte β_2-adrenoceptor function in asthmatic and normal subjects, 554P
NICHOLLS, D. P. *see* NUGENT, A. M.
NICHOLLS, D. P. *see* RILEY, M.
NICHOLSON, P. W. *see* WELLER, C.
NILSSON, D. *see* LENNERNÄS, H. A.
NILSSON, L. R. *see* MOVIN-OSSWALD, G.
NISHIHARA, K. *see* BLOUIN, R.
NJUNJU, E. *see* SIMOOYA, O. O.
NOTARIANNI, L. J., BELK, D. & BENNETT, P. N. Estimation of drug entry into breast milk: an *in vitro* model, 532P
NUGENT, A. M., BELL, N., NEELY, D., MCDOWELL, I., YOUNG, I., O'KANE, M. & NICHOLLS, D. P. Simvastatin treatment and the stress response in hyperlipidaemia, 553P
NUNAN, T. O. *see* THOMAS, S. H. L.
NURMOHAMED, M. T. *see* GIANESE, F.
NURMOHAMED, M. T. The pharmacokinetics and pharmacodynamics of dermatan sulphate MF701 during haemodialysis for chronic renal failure, 335
NYBERG, G., JOHANSSON, P., JONSSON, U., LIDMAN, K. & SVERNHAGE, E. A pharmacokinetic study of controlled-release isosorbide-5-mononitrate (5-ISMN) with concomitant quantitation of the intensity of headache, 69P

O'CONNOR, B. J., LECOMTE, J. M. & BARNES, P. J. Effect of an inhaled histamine H_3-receptor agonist on airway responses to sodium metabisulphite in asthma, 55
O'DOHERTY, M. J. *see* THOMAS, S. H. L.
O'KANE, M. *see* NUGENT, A. M.
O'NEILL, C. J. A. *see* CHARLETT, A.
O'NEILL, C. J. A. *see* WELLER, C.
O'SHEA, D. & WILKINSON, G. R. 6-hydroxylation of chlorzoxazone —a putative *in vivo* probe for cytochrome P4502E1 activity in humans, 532P
OHTAWA, M., TAKAYAMA, F., SAITOH, K., YOSHINAGA, T. & NAKASHIMA, M. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans, 290
OLDHAM, A. A. *see* SMITH, S. J.
OLIVER, I. *see* DUTERTRE, J. P.
OMARI, T. I., SPARROW, M. P. & MITCHELL, H. W. Responsiveness of human isolated bronchial segments and its relationship to epithelial loss, 357
ON, N. T. *see* ROLAN, P. E.
ONUOHA, G. *see* RILEY, M.
ORLOFF, A. M. *see* MARRE, F.
OTTON, S. V. *see* WU, D.

PAALZOW, L. K. *see* LENNERNÄS, H.
PAGE, C. J. *see* THOMAS, S. H. L.
PAINTAUD, G., ALVÁN, G. & ERICSSON, O. The reproducibility of quinine bioavailability, 305
PALMER, J. L. *see* BLAKE, J. C.
PALMÉR, M. *see* VILLANUEVA, M.
PARKER, B. M. *see* LOI, C.-M.
PARKER, J. E. *see* ROLAN, P. E.
PATEL, I. H. *see* HALLAK, H. O.
PATEL, M. *see* JOHNSTON, A.
PAULY, N. *see* BEVAN, E. G.
PEAKE, I. R. *see* YEO, W. W.
PECK, R. W., CROME, P., WEATHERLEY, B. C. & POSNER, J. Tolerability and pharmacokinetics of 882C, a nucleoside analogue, in healthy elderly volunteers, 74P
PECK, R. W., WOOTTON, R., LEE, D. R., JACKSON, S. H. D. & POSNER, J. Pharmacokinetics of oral and intravenous 882C [1-9β-D-arabinofuranosyl)-5-(1-propynyl) uracil], a thymidine analogue with anti varicella zoster virus activity, in young and elderly volunteers, 546
PEDEN, N. R. *see* FEELY, J.
PELL, P. *see* SHELDON, P.
PESOLA, G. R. *see* WALLE, U. K.
PETRIE, J. C. *see* FOWLER, G.
PETRIE, J. C. *see* LYONS, D.
PETRIE, J. C. *see* WEBSTER, J.
PICKARD, R. S., POWELL, P. H. & ZAR, M. A. Comparison of neurogenic nitric oxide formation in cavernosal tissue from potent and impotent men, 536P
PICKERING, A. *see* POWELL, J.
PIETERS, M. S. M. *see* STEVENINCK VAN, A. L.
PIPER, P. J. *see* BARKER, J. E.
PLEUVRY, B. J. *see* WILDIN, J. D.
PLUMPTON, C. *see* SUN, B.
POIRIER, L. *see* LACOURCIERE, Y.
POLK, R. E. *see* SAHAI, J.
POSNER, J. *see* PECK, R. W.
POSNER, J. *see* ROLAN, P. E.
POWELL, J., PICKERING, A., WYKE, M. & GOGGIN, T. The effects of antihypertensive medication on learning and memory, 105
POWELL, P. H. *see* PICKARD, R. S.
PRATT, S. K., FAIRLESS, A. J., PUE, M. A., FOWLES, S. E., LAROCHE, J., GEORGIOU, P. & PRINCE, W. T. Linearity of the pharmacokinetics of penciclovir following oral administration of famciclovir over the therapeutic dose range 125 to 750 mg, 80P
PRESCOTT, L. F., FREESTONE, S. & MCAUSLANE, J. A. N. The concentration-dependent disposition of intravenous *p*-aminohippurate in subjects with normal and impaired renal function, 20
PRINCE, W. T. *see* PRATT, S. K.
PROVENCHER, P. *see* LACOURCIERE, Y.
PUE, M. A. *see* PRATT, S. K.
PUKRITTAYAKAMEE, S. *see* EDWARDS, G.
PULLAR, T. Book review: Adverse reactions to non-steroidal anti-inflammatory drugs: clinical pharmacoepidemiology, 340
PURKISS, A. *see* WELLER, C.

QUINN, M. *see* HARTLEY, R.

RAHMAN, A. R. *see* LANG, C. C.
RAHMANI, R. *see* MARRE, F.
RAMSAY, L. E. Bridging the gap between clinical pharmacology and rational drug prescribing, 575
RAMSAY, L. E. *see* HAQ, I.
RAMSAY, L. E. *see* YEO, W. W.
RAWLINS, M. D. & JEFFERYS, D. B. United Kingdom Product Licence applications involving new active substances, 1987–1989; their fate after appeals, 599
RAWLINS, M. D. *see* FORD, G. A.
RAWLINS, M. D. *see* KAMALI, F.
RAY-CHAUDHURI, K., THOMAIDES, T., MAULE, S., WATSON, L., LOWE, S. & MATHIAS, C. J. The effect of captopril on the superior mesenteric artery and portal venous blood flow in normal man, 517
REID, J. L. *see* MACFADYEN, R. J.
REID, J. L. *see* MORRIS, A. D.
REID, J. L. The role of clinical pharmacology in the development and assessment of drugs for cerebrovascular disease and stroke, 341
REINHOUDT, J. F. *see* VAN ROOIJ, J.
RIDDELL, J. G. *see* GUY, S.
RIETBROCK, S. *see* WOODCOCK, B. G.
RILEY, M., ELBORN, J. S., ONUOHA, G., ERWIN, C., SHAW, C., KHAN, M. M., STANFORD, C. F. & NICHOLLS, D. P. Effect of β-adrenoceptor blockade on atrial natriuretic peptide levels during exercise in angina pectoris, 209
RITTER, J. M. *see* BARROW, S. E.
RITTER, J. M. *see* CHOWIENCZYK, P. J.
RITTER, J. M. *see* COCKCROFT, J. R.
ROBERTS, C. J. C. *see* FORD, J. M.
ROBERTS, M. S. *see* SHEN, J.
ROBERTS, P. *see* TSANG, K. T.
RODERICK, P. J., WILKES, H. C. & MEADE, T. W. The gastro-intestinal toxicity of aspirin: an overview, 219
RODKÍGUEZ, C., ARNAU, J. M., VIDAL, X. & LAPORTE, J. R. Therapeutic consultation: a necessary adjunct to independent drug information, 46
ROLAN, P. E., MAILLOT, F., ON, N. T. & POSNER, J. The effects of cimetidine and probenecid on the conversion of a valine ester of acyclovir, 256U, to acyclovir and acyclovir renal clearance in healthy volunteers, 533P
ROLAN, P. E., PARKER, J. E., GRAY, S. J., WEATHERLY, B. C., INGRAM, J., LEAVENS, W. WOOTTON, R. & POSNER, J. The pharmacokinetics, tolerability and pharmacodynamics of tucaresol (589C80; 4[2-formyl-3-hydroxyphenoxymethyl] benzoic acid), a potential anti-sickling agent, following oral administration to healthy subjects, 419
RONCARI, G. *see* BURY, M.
ROOS, B.-E. *see* ECKERNAS, S.-A.
ROSTAMI HODJEGAN, A. *see* SIMOOYA, O. O.
ROUSSEAU, F. S. *see* WILLIAMS, P. E. O.
RUBIN, P. *see* HYMNA-TAYLOR, P.
RUBIN, P. C. *see* AJAYI, A. A.

SABRA, K. *see* CHAN, R.
SAETTONE, M. F. *see* LAHDES, K.
SAHAI, J., HEALY, D. P., STOTKA, J. & POLK, R. E. The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin, 302
SAHINOGLU, T. *see* NAZHAT, N. B.

SAITOH, K. *see* OHTAWA, M.
SALMINEN, L. *see* LAHDES, K.
SAMANTA, A. *see* TAYLOR, H. G.
SANGHERA, S. S. *see* FOWLER, G.
SANGHERA, S. S. *see* WEBSTER, J.
SARIKOUCH, S. *see* BRODDE, O.-E.
SCARTH, B. *see* DAHLOF, B.
SCHOEMAKER, H. C. *see* BURGGRAAF, J.
SCHOEMAKER, H. C. *see* COHEN, A. F.
SCHOEMAKER, H. C. *see* KROON, C.
SCHOEMAKER, H. C. *see* VAN GRIENSVEN, J. M. T.
SCHOEMAKER, H. C. *see* VAN ROOIJ, J.
SCHOEMAKER, H. C. *see* VAN STEVENINCK, A. L.
SCHOEMAKER, H. C. *see* WALLNOFER, A. E.
SCHÖR, K. *see* VILLANUEVA, M.
SCHUTT, B. *see* DUKA, T.
SCOTT, A. *see* WALLEY, T.
SCOTT, M. E. *see* SILKE, B.
SEDDON, R. J. *see* SHEN, J.
SEIDEMAN, P., BECK, O., EKSBORG, S. & WENNBERG, M. The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis, 409
SELLERS, E. M. *see* WU, D.
SERENI, D. *see* WILLIAMS, P. E. O.
SEVER, P. S. *see* MACKAY, J.
SEVER, P. S. *see* SUNMAN, W.
SHAH, G. *see* JOHNSTON, A.
SHAW, C. *see* RILEY, M.
SHELDON, P. & PELL, P. Comparison of the effect of oral sulphasalazine, sulphapyridine and 5-amino-salicylic acid on the *in vivo* antibody response to oral and systemic antigen, 261
SHEN, J., WANWIMOLRUK, S., WILSON, P. D., SEDDON, R. J. & ROBERTS, M. S. A clinical trial of a slow release formulation of acetylsalicylic acid in patients at risk for preeclampsia, 664
SHERIDAN, D. J. *see* DAVIES, R. H.
SHORROCK, C. J. *see* MARRIOTT, J. F.
SIDHU, J. S., TRIGGS, E. J., CHARLES, B. G. & SMITHURST, B. A. Individual theophylline dosing based on bioelectrical impedance analysis, 657
SILKE, B. *see* GUY, S.
SILKE, B. *see* JASSAL, V.
SILKE, B. *see* THAM, T. C. K.
SILKE, B., BOYD, S., MCPARLAND, C. & SCOTT, M. E. Validation of a continuous non-invasive blood pressure method (Finapres), 88P
SIMONS, J. *see* JOHNSON, A. G.
SIMONS, L. A. *see* JOHNSON, A. G.
SIMOOYA, O. O., NJUNJU, E., ROSTAMI HODJEGAN, A., LENNARD, M. S. & TUCKER, G. T. Debrisoquine and metoprolol oxidation in Zambians: a population study, 549P
SINCLAIR, J. H. *see* SUN, B.
SINGH, D. *see* NAZHAT, N. B.
SJÖGREN, A. *see* FAGHER, B.
SKJELBO, E., GRAM, L. F. & BRØSEN, K. The *N*-demethylation of imipramine correlated with the oxidation of S-mephenytoin (S/R-ratio). A population study, 331
SMITH, S. J., OLDHAM, A. A., YATES, A., SWEENEY, M. & WILLIAMS, A. J. An angiotensin II antagonist (ICI D8731) inhibits the angiotensin II pressor response in healthy volunteers, 67P
SMITHURST, B. A. *see* SIDHU, J. S.
SPARROW, M. P. *see* OMARI, T. I.
SPATZ, D. *see* BROCKMEYER, N. H.
SPATZ, D., BROCKMEYER, N. H., TILLMAN, I., MERTINS, L. & GOOS, M. Effect of fusidic acid on antipyrine pharmacokinetics parameters, 545P
SPROULE, B. A. *see* WU, D.
STANFORD, C. F. *see* RILEY, M.
STEVENINCK VAN, A. L., PIETERS, M. S. M., SCHOEMAKER, H. C., BREIMER, D. D. & COHEN, A. F. CNS-related performance and haemodynamics of metoprolol-Oros and propranolol after single and 3 days dosing in healthy volunteers, 114
STEVENSON, I. H. & MORELAND, T. A. Letter to the Editors. Back-estimation of blood alcohol concentration, 669
STEVENSON, I. H. *see* FEELY, J.
STEWART JOHNSON, F. *see* CARVER, J. G.
STEWART, G. A. *see* TAYLOR, M. L.
STOCK, K. P. *see* GEISSLINGER, G.
STOTKA, J. *see* SAHAI, J.
STRATTON, P. D. *see* BARROW, S. E.
STRICKER, B. H. CH. *see* VAN DER KLAUW, M. M.
STROBACH, H. *see* VILLANUEVA, M.
STROLIN-BENEDETTI, M. *see* JOHNSTON, A.
STRUTHERS, A. D. *see* LANG, C. C.
STRUTHERS, A. D. *see* STURROCK, N. D. C.
STUDHAM, J. *see* CHOUDRY, N. B.
STURROCK, N. D. C. & STRUTHERS, A. D. Non-steroidal anti-inflammatory drugs and angiotensin converting enzyme inhibitors: a commonly prescribed combination with variable effects on renal function, 343
STURROCK, N. D. C., LANG, C. C. & STRUTHERS, A. D. Acute cyclosporin reduces urinary water output and increases blood pressure before renal blood flow and renal sodium output are affected, 72P
SUN, B., PLUMPTON, C., SINCLAIR, J. H. & BROWN, M. J. Comparison of plasmid- and retrovirus-mediated gene expression in cultured human endothelial cells, 554P
SUNMAN, W., SEVER, P. S. & HUGHES, A. D. The interaction between *N*-acetylcysteine, the superoxide anion and the endothelium in isolate resistance arteries, 89P
SUPANARANOND, W. *see* EDWARDS, G.
SVERNHAGE, E. *see* NYBERG, G.
SWEENY, M. *see* SMITH, S. J.

TADJKARIMI, S. *see* MIURA, M.
TAKAYAMA, F. *see* OHTAWA, M.
TAYLOR, A. C. *see* BEERAHEE, A.
TAYLOR, H. G. & SAMANTA, A. Treatment of vasculitis, 93
TAYLOR, M. L., STEWART, G. A. & THOMPSON, P. J. The differential effect of aspirin on human platelet activation in aspirin-sensitive asthmatics and normal subjects, 227
TEN CATE, J. W. *see* GIANESE, F.
TETTAMANTI, F. *see* FOGARI, R.
THAM, T. C. K., HERITY, N., GUY, S. & SILKE, B. Echo-Doppler haemodynamic comparison of amlodipine and atenolol in essential hypertension, 85P
THANAVIBUL, A. *see* KARBWANG, J.
THOMAIDES, T. *see* RAY-CHAUDHURI, K.
THOMAS, S. H. L. *see* KAMALI, F.
THOMAS, S. H. L., O'DOHERTY, M. J., GIBB, D., PAGE, C. J., HARRINGTON, C., DUGGAN, C., NUNAN, T. O. & BATEMAN, N. T. Pulmonary deposition of nebulized pentamidine in children with HIV infection, 83P
THOMPSON, J. M. *see* BELCH, J. J. F.
THOMPSON, P. J. *see* TAYLOR, M. L.
TILLMANN, I. *see* BROCKMEYER, N. H.
TILLMANN, I. *see* SPATZ, D.
TOMLINSON, B. *see* ANDERSON, P. J.
TRAMONTANA, M. *see* GEPPETTI, P.
TREASURE, T. *see* BARKER, J. E.
TRIGGS, E. J. *see* SIDHU, J. S.
TROWBRIDGE, A. A. *see* HALLAK, H. O.
TRUMAN, C. A. *see* FORD, J. M.
TSANG, K. T., ROBERTS, P., READ, R., COLES, S. J., WILSON, R. & COLE, P. J. The concentration of clarithromycin and its active 14-hydroxy metabolite in sputum of patients with bronchiectasis following single dose oral administration, 84P
TSAO, Y. *see* WALLEY, T.
TUCKER, G. T. *see* HAQ, I.
TUCKER, G. T. *see* SIMOOYA, O. O.
TURNER, P. *see* JOHNSTON, A.
TURNER, P. *see* LI KAM WA, T. C.
TURNER, P. *see* MUNROE, P. B.

UEMATSU, T., NAKANO, M., AKIYAMA, H. & NAKASHIMA, M. The measurement of a new antimicrobial quinolone in hair as an index of drug exposure, 199
UNWIN, R. J. *see* CLIFFORD, P.

VALKENBURG, H. A. *see* VAN DER KLAUW, M. M.
VALLANCE, P. J. T. *see* CALVER, A. L.
VAN BERCKEL, B. N. M. *see* VAN STEVENINCK, A. L.
VAN BRUMMELEN, P. *see* BURY, M.
VAN DEN BIGGELAAR-MARTEA, M. *see* VREE, T. B.
VAN DER KLAUW, M. M., STRICKER, B. H. CH., HERINGS, R. M. C., COST, W. S., VALKENBURG, H. A. & WILSON, J. H. P. A population based case-cohort study of drug-induced anaphylaxis, 400
VAN DER MEER, F. J. M. *see* VAN ROOIJ, J.
VAN GRIENSVEN, J. M. T. *see* WALLNOFER, A. E.
VAN GRIENSVEN, J. M. T., LEMKES, H. H. P. J., KROON, J. M., SCHOEMAKER, H. C. & COHEN, A. F. The pharmacokinetics and pharmacodynamics of tolrestat in normal volunteers and patients with insulin dependent diabetes mellitus, 547P
VAN MANDACH, U., BÜRGI, M., HUCH, R. & HUCH, A. Magnesium sulphate increases lymphocyte adenosine 3′:5′-cyclic monophosphate in humans, 324
VAN ROOIJ, J., SCHOEMAKER, H. C., BRUNO, R., REINHOUDT, J. F., BREIMER, D. D. & COHEN, A. F. Cimetidine does not influence the metabolism of the H_1-receptor antagonist ebastine to its active metabolite carebastine, 661
VAN ROOIJ, J., VAN DER MEER, F. J. M., SCHOEMAKER, H. C. & COHEN, A. F. Comparison of the effect of grapefruit juice and cimetidine on pharmacokinetics and anticoagulant effect of a single dose of acenocoumarol, 548P
VAN STEVENINCK, A. L., VAN BERCKEL, B. N. M., SCHOEMAKER, H. C., BREIMER, D. D. & COHEN, A. F. Sensitivity of CNS performance tests to the effects of sleep deprivation, 551P
VAN VLIET-VERBEEK, A. *see* COHEN, A. F.
VAN ZWIETEN, P. A. *see* BRUNING, T. A.
VANAKOSKI, J. *see* MATTILA, M. J.
VANDENBURG, M. *see* WALLEY, T.
VERE, D. W. *see* LOPEZ-GIL, J. A.
VERMEIJ, P. *see* BRUNING, T. A.
VERWEYVAN WISSEN, C. P. W. G. M. *see* VREE, T. B.
VESTAL, R. E. *see* LOI, C.-M.
VIDAL, X. *see* RODRIGUEZ, C.
VILLANUEVA, M., HECKENBERGER, R., STROBACH, H., PALMÉR, M. & SCHÖR, K. Equipotent inhibition by R(−)-, S(+)-racemic ibuprofen of human polymorphonuclear cell function *in vitro*, 235
VINCENT-VIRY, M. *see* MURA, C.
VREE, M. L. *see* VREE, T. B.
VREE, T. B., VAN DEN BIGGELAAR-MARTEA, M., VERWEYVAN WISSEN, C. P. W. G. M., VREE, M. L. & GUELEN, P. J. M. The pharmacokinetics of naproxen, its metabolite *O*-desmethylnaproxen, and their acyl glucuronides in humans. Effect of cimetidine, 467

WALKER, R. *see* ANDERSON, P. J.
WALLE, T. *see* WALLE, U. K.
WALLE, U. K., PESOLA, G. R. & WALLE, T. Stereoselective sulphate conjugation of salbutamol in humans: comparison of hepatic, intestinal and platelet activity, 413
WALLÉN, N. H., LARSSON, P. T., BROIJERSEN, A., ANDERSSON, A. & HJEMDAHL, P. Effects of an oral dose of isosorbide dinitrate on platelet function and fibrinolysis in healthy volunteers, 143
WALLEY, T., TSAO, Y., SCOTT, A., MACKAY, E., VANDENBURG, M. & BRECKENRIDGE, A. Effects of dilevalol and nifedipine on heart rate, blood pressure and muscle blood flow before and after exercise in hypertensive patients, 86P
WALLEY, T., TSAO, Y., SCOTT, A., MACKAY, E., VANDENBURG, M. & BRECKENRIDGE, A. Effects of dilevalol (R,R-labetalol) compared with nifedipine on heart rate, blood pressure and muscle blood flow at rest and on exercise in hypertensive patients, 623
WALLNOFER, A. E. & COHEN, A. F. Good clinical practice: a question of balance, 449
WALLNOFER, A. E., VAN GRIENSVEN, J. M. T., KOOISTRA, T., KLUFT, C., MEIJER, P., LAMBERT, W., SCHOEMAKER, H. C. & COHEN, A. F. Effect of isotretinoin on endogenous t-PA and PAI-1, 543P
WANWIMOLRUK, S. *see* SHEN, J.
WARD, J. K. *see* MIURA, M.
WARD, S. A. *see* EDWARDS, G.
WARD, S. A. *see* HELSBY, N. A.
WATSON, L. *see* RAY-CHAUDHURI, K.
WATSON, P. *see* MACKAY, J.
WEATHERLEY, B. C. *see* PECK, R. W.
WEATHERLEY, B. C. *see* ROLAN, P. E.
WEBSTER, J. *see* FOWLER, G.
WEBSTER, J. *see* LYONS, D.
WEBSTER, J., FOWLER, G., JEFFERS, T. A., LYONS, D., WITTE, K., CRICHTON, W. A., WICKHAM, E. A., SANGHERA, S. S., CORNISH, R. & PETRIE, J. C. A comparison of amlodipine with enalapril in the treatment of isolated systolic hypertension, 499
WEDLUND, P. J. *see* HALLAK, H. O.
WEI, X. *see* LOI, C.-M.
WELLER, C., O'NEILL, C. J. A., CHARLETT, A., BOWES, S. G., PURKISS, A., NICHOLSON, P. W., DOBBS, R. J. & DOBBS, S. M. Defining small differences in efficacy between anti-Parkinsonian agents using gait anaysis: a comparison of two controlled release formulations of levodopa/decarboxylase inhibitor, 379
WEN, H., NEW, R. R. C. & CRAIG, P. S. Diagnosis and treatment of human hydatidosis, 557P
WENNBERG, M. *see* SEIDEMAN, P.
WHEELDON, N. M. *see* GERRARD, L.
WHEELDON, N. M., MCDEVITT, D. G. & LIPWORTH, B. J. Investigation of putative cardiac β_3-adrenoceptors in man, 87P
WHEELDON, N. M., MCDEVITT, D. G., MCFARLANE, L. C. & LIPWORTH, B. J. Evaluation of the presence of putative β_3-adrenoceptors mediating the metabolic responses to isoprenaline, 555P
WHITE, N. J. *see* EDWARDS, G.
WHITE, N. J. *see* KARBWANG, J.
WICKHAM, E. A. *see* FOWLER, G.
WICKHAM, E. A. *see* WEBSTER, J.
WILCOCK, G. K. *see* FORD, J. M.
WILDIN, J. D., PLEUVRY, B. J. & MAWER, G. E. Impairment of psychomotor function at modest plasma concentrations of carbamazepine after administration of the liquid suspension to naive subjects, 14
WILKES, H. C. *see* RODERICK, P. J.
WILKINS, M. R. *see* CLIFFORD, P.
WILKINSON, G. R. *see* O'SHEA, D.
WILKINSON, R. *see* BEVAN, E. G.
WILLIAMS, A. J. *see* MURDOCH, R. D.
WILLIAMS, A. J. *see* SMITH, S. J.
WILLIAMS, P. E. O., MUIRHEAD, G. J., SERENI, D., ROUSSEAU, F. S., EDELMAN, K. & HOOKER, M. Pharmacokinetics of 2-fluorodideoxycytidine (2FddC) in patients infected with human immunodeficiency virus, 255
WILSON, C. G. *see* GREAVES, J. L.
WILSON, J. H. P. *see* VAN DER KLAUW, M. M.

WILSON, P. D. *see* SHEN, J.
WILSON, R. *see* TSANG, K. T.
WITTE, K. *see* FOWLER, G.
WITTE, K. *see* WEBSTER, J.
WOOD-BAKER, R., EMANUEL, M. B., HUTCHINSON, K. & HOWARTH, P. H. The time course of action of three differing doses of noberastine, a novel H_1-receptor antagonist, on histamine-induced skin wheals and the relationship to plasma drug concentrations in normal human volunteers, 166
WOODCOCK, B. G., RIETBROCK, S. & MERZ, P. G. Absorption characteristics of the inclusion complex piroxicam β-cyclodextrin administered after food, 546P
WOODRUFF, B. *see* HALLAK, H. O.
WOOTTON, R. *see* PECK, R. W.
WOOTTON, R. *see* ROLAN, P. E.
WU, D., OTTON, S. V., SPROULE, B. A., BUSTO, U., INABA, T., KALOW, W. & SELLERS, E. M. Inhibition of human cytochrome P450 2D6 (XYP2D6) by methadone, 30
WYKE, M. *see* POWELL, J.

YACOUB, M. H. *see* MIURA, M.
YATES, A. *see* SMITH, S. J.
YEO, W. W. *see* HAQ, I.
YEO, W. W., HIGGINS, K. S., MORICE, A. H., JACKSON, P. R., PEAKE, I. R. & RAMSAY, L. E. Investigation of relation between ACE gene polymorphism and ACE inhibitor cough, 66P
YOSHINAGA, T. *see* OHTAWA, M.
YOULTEN, L. J. F. *see* MURDOCH, R. D.
YOUNG, I. *see* NUGENT, A. M.

ZAR, M. A. *see* PICKARD, R. S.
ZELL, M. *see* BURY, M.
ZERKOWSKI, H.-R. *see* BRODDE, O.-E.

SUBJECT INDEX

This index was compiled from the keywords

(P = proceedings)

Absorption, 171
ACE gene, 66p
ACE inhibitor, 66P
Acenocoumarol, 548
Acetyl-PAH, 20
Acetylation, 20, 21
Acetylcholine, 542P
Acetylsalicylic acid, 664
Activated renin angiotensin systems, 299
Acyclovir, 533P
Acyl glucuronide, 467
Adenylate cyclase, 70P
Adrenaline, 143
Adverse drug reactions, 400
Adverse reactions, 82P, 340, 536P
Ageing, 70P
Albuterol, 413
Alcohol, 669
α_1-acid glycoprotein, 615
α-adrenoceptor selectivity, 541P
Ambulatory blood pressure monitoring, 51
Ambulatory hypertension, 121
Amiloride, 373
Amitriptyline, 278
Amlodipine, 85P, 491, 499
Amodiaquine, 215P
Amoxycillin, 400
Anaphylaxis, 400
Angina pectoris, 209
Angiotensin, 525
Angiotensin II, 88P, 517, 538P
Angiotensin II antagonist, 67P, 290
Angiotensin converting enzyme, 528
Angiotensin converting enzyme inhibitors, 343
Anti-cyclosporin A, 90P
Anti-inflammatory agents, 455
Anti-sickling agent, 419
Anticoagulant effect, 548P
Antidepressant, 76P
Antihypertensive, 81P
Antihypertensive drugs, 536P
Antimalarial, 193, 215P
Antinociceptive, 73P
Antipyrine, 243, 534P, 545P
Antithrombotic, 355
Anxiolytic, 386
Aprindine, 426
1-(β-D-arabinofuranosyl)-5-(1-propynyl)uracil, 546P
Aspirin, 219, 227
Assessment, 591
Asthma, 1, 55, 227, 554P
ATI-receptor antagonist, 88P
Atenolol, 70P, 85P, 105, 121, 507, 552P
ATP-sensitive potassium channels, 318
Atrial natriuretic factor, 90P, 209
Attitude, 204
Autonomic blockade, 70P, 543P
β-adrenoceptor antagonist, 77P
β_1-adrenoceptor antagonist, 537P, 542P
β-adrenoceptor blockade, 209
β_1-adrenoceptor blockade, 539P
β-adrenoceptor density, 70P
β-adrenoceptors, 629
β_1-adrenoceptors, 35
β_1-receptor occupancy, 507
β_2-adrenoceptor, 35, 324
β_2-adrenoceptor blockade, 539P
β_2-adrenoceptor sensitization, 539P
β_2-adrenoceptors, 71P
β_3-adrenoceptors, 87P, 555P
β_2-receptor blockade, 461
β_2-receptor occupancy, 507
β-carboline, 386
β-thromboglobulin, 143
BRL 46470A, 395
Back extrapolation, 669
Behavioural toxicity, 278
Bendrofluazide, 552P
Benzimidazoles, 565
Benzodiazepine hypnotic, 533P
Bioavailability, 76P, 136, 308, 535
Bioelectrical impedance, 657
Bioequivalence, 80P
Blood pressure, 114, 299
Book review, 340
Bovine bronchial segment, 357
Brachial artery, 542P
Bradykinin, 8, 178
Bradyphrenia, 84P
Breast milk, 532P
4-bromo-oestradiol, 216P
2-bromo-oestradiol, 216P
Bronchodilatation, 318
Bronchial epithelium, 357
Bronchiectasis, 84P
Bronchoconstriction, 184
Bunazosin, 541P

Caffeine, 40, 51, 77P, 431, 535
Calcium antagonist, 40
Capsaicin, 178, 184
Captopril, 8, 517
Carbamazepine, 14, 216P, 311
Carebastine, 272
Case-cohort study, 400
Cavernosal tissue, 536
Celiprolol, 71
Cerebrovascular disease, 341
Chemotherapy, 565
Children, 311
Chirality, 235
Chlorzoxazone, 532P
Cicaprost, 643
Cilazapril, 66P, 105
Cimetidine, 467, 533P, 548P, 661
Ciprofloxacin, 78
Citric acid, 178
Clarithromycin, 84
Clinical pharmacology, 341, 575, 577, 581, 587, 591
Clinical trials, 204
CNS penetration, 284
CNS performance 550P
CYP1A2, 431
CYP2D6, 30, 73P, 426
Concentration-dependent clearance, 20
Congestive heart failure, 528
Controlled release, 69P, 80P, 379
Converting enzyme, 525
Corticosteroid, 637
Cough, 66P, 184
Cyclic AMP, 1, 324
Cyclic GMP, 1
Cyclopentolate, 479
Cyclosporin, 72P, 447
Cyclosporine A, 156
Cytochrome P450, 215P, 431
Cytochrome P4502D6, 161
Cytochrome P4502E1, 532P

Dalteparin, 90P
Debrisoquine, 161, 549P
Demethylation, 331
Dermatan sulphate, 335
Desmethyldiazepam, 78P
Development, 314
Dextromethorphan oxidation, 30
Diabetes, 321
Diabetes mellitus, 58, 547P
Diabetic patients, 91P
Diagnosis, 565
Diazepam, 78P
Diazepam interaction, 272
Diclofenac, 400
2′-3′-dideoxycytidine, 214P
Diflunisal, 609
Digoxin, 136, 535P
Digoxin-like immunoreactivity, 251
Dilevalol, 86P, 623
Diuresis, 609
Diuretic, 152, 373
Dose dependency, 461
Drug assay, 79P
Drug choice, 591
Drug information, 46
Drug interaction, 437
Drug prescribing, 581
Drug recognition, 549P
Drug regulation, 599
Drug utilization, 217P

EEG, 395
Ebastine, 272, 661
Echinococcosis, 565
Echo-Doppler, 71P, 85P, 87P, 548P
Education, 581
Effective renal plasma flow, 20, 21
882C, 74P, 546P
Elderly, 74P, 76P, 455

Elderly volunteers, 278
Electrolytes, 629
Electron spin resonance spectroscopy, 79P
Enalapril, 8, 299, 491, 499, 528
Enantiomers, 603
Endothelial cells, 554P
Endothelial-derived relaxing factor,485
Endothelium, 538P
Enoxaparin, 90P
Epithelial denudation, 357
Epithelial stripping, 357
Erythromycin, 77P
Ethnic differences, 549P
Ethnic groups, 66P
Euglycaemic clamp, 40
Excretion, 171
Exercise, 209, 623
Exercise heart rate, 114

Famciclovir, 80P
Famotidine, 543
Felodipine, 92P
Fengabine, 278
Fetal arrhythmias, 251
Fetus, 251
Filtragometry, 143
Finapres, 88P
Fish oil, 91P
5-hydroxytryptophan, 68P
Flavanones, 431
2-fluorodideoxy-cytidine, 255
Flurbiprofen, 62
Food, 548P
Food effects, 308
Food–drug interaction, 431
Foot separation, 379
Forearm, 68P
Forearm blood flow, 68P, 525, 542P
Forearm length, 542P
Formularies, 550P
Formulation, 14
Fusidic acid, 545P

Gamma scintigraphy, 188
Gastrointestinal bleeding, 219
GBR 12909, 308
Genetic polymorphism, 653
Genotype, 161
Glafenine, 400
Glucose, 243
Glucuronidation, 314
Glucuronide, 609
Gludopa, 74P
Good clinical practice, 449
Grapefruit, 431
Grapefruit juice, 548P
GR117289C, 188P

HDL, 91P
HIV infection, 83P, 214P
HIV-1, 255, 534P
Haemodialysis, 335
Haemorrhage, 451
Hair growth rate, 199
Heart failure, 1, 71P, 538P, 539P, 557
Heparin, 90P
Hepatic impairment, 76P, 441
Hepatitis, 444
Histamine, 55, 171
Histamine H_2-receptor antagonists, 543P
Histamine H_3-receptor, 55P, 545P
Histamine-induced skin wheal, 166
Home monitoring, 311
H_2-receptor, 55
H_2-receptor antagonist, 321
5-HT, 68P, 473
5-HT_3, 395
[^{3}H]-5-HT efflux, 473
Human, 386, 485
Human bladder, 366
Human bronchi, 318
Human bronchial segment, 357
Human intestine, 413
Human liver, 413
Human liver microsomes, 30
Human nasal mucosa, 178
Human neutrophils, 235
Human platelets, 413
Human volunteers, 290
Hydrochlorothiazide, 373
7-hydroxymethotrexate, 409
Hydroxypropylmethylcellulose, 188
Hyperlipidaemia, 553P
Hypertension, 51, 85P, 86P, 68P, 105, 455, 540, 541, 623, 664
Hypertonic saline, 178
Hypoglycaemia, 321

Ibopamine, 539P
Ibuprofen, 235, 603
ICI D8731, 67P
Imipramine, 331
Impedance cardiography, 349
Index of exposure, 199
Infants, 528
Inflammation, 637
Inflammatory bowel disease, 261
Inhibition, 426
Insulin, 540P
Insulin resistance, 40
Interaction, 77P, 156, 321, 447, 467, 535P, 661
Interferon, 534P
Intestinal absorption, 305
Intestinal perfusion, 243
Intestinal permeability, 243
Isolated systolic hypertension, 499
Isoprenaline, 349, 555P
Isosorbide dinitrate, 143
Isosorbide-5-mononitrate, 69P
Isotretinoin, 543P
Isradipine, 51

Kidney failure, 335

Lacidipine, 35, 40, 85P
Laser Doppler flowmetry, 8, 105, 643
Learning, 105
Leucine, 243
Leukotrienes, 235
Levcromokalim, 81P, 82P
Levodopa, 243, 379
Lipophilicity, 284
Liver disease, 62
L-NMMA, 68P
Losartan, 290
Low molecular weight heparin(oids), 535P
Lumbar CSF, 507
Lymphoblastic anaemia, 75P
Lymphocyte β_2-adrenoceptor function, 554P
Lymphocytes, 324
Lyso-PAF, 637

Macrolide antibiotics, 447
Magnesium, 373
Magnesium sulphate, 324
Malaria, 193
Man, 525, 615
m-CPP, 473
Medical therapy, 557
Medication errors, 152
Memory, 105
Mephenytoin, 331
Metabolic responses, 555P
Metabolism, 58, 136, 161, 437, 615
Metabolites, 615
Methadone, 30
Methotrexate, 409
Metoprolol, 92, 114, 507, 549
Midazolam, 77P
Mirtazapine, 76P
Moclobemide, 649
Model system, 299
Moderate/severe hypertension, 491
Monoamine oxidase B inhibitor, 74P
Monoamine oxidase inhibition, 184
Morphine, 314
Motivation, 204
Mucoadhesion, 479
Mucosal immunity, 261
Multiple dose, 386, 653

N-acetylcysteine, 89P
Na-K pump, 629
Naloxone, 73P
Naproxen pharmacokinetics, 467
Naringenin, 431
Naringin, 431
Nebivolol, 537P, 542P
Negative chronotropism, 461
Neonates, 314
Neuroleptic, 615
New active substances, 599
N^G-monomethyl-L-arginine, 68P
Nicergoline, 80P
Nifedipine, 76P, 86P, 105, 623
Nitric oxide, 68P, 366, 536P
Nizatidine, 461, 543P
Noberastine, 166
Non-invasive blood pressure method, 88P
Non-invasive predictive models, 657
Non-linear kinetics, 20
Non-steroidal, 455
Non-steroidal anti-inflammatory drugs, 340, 343, 544P
Nucleoside analogue, 74P, 214P

Ocular therapy, 479
Odansetron, 441
Olive oil, 91P
Omeprazole, 156
OPC-17116, 199
Ophthalmic ointment, 188

Oral absorption, 243
Oral prostacyclin, 643

PAF, 637
Pain, 553P
p-aminohippurate, 20, 21
Paracetamol, 58
Parkinsonism, 84P, 379
Partial agonist activity, 71P
Patient knowledge, 152
Penciclovir, 80P
Pentamidine, 83P
Peptic ulcer, 451
Perfused platelets, 473
Pharmacodynamics, 85P, 128, 265, 335, 419, 533P, 547P, 623
Pharmacoepidemiology, 400
Pharmacokinetics, 69P, 74P, 75P, 76P, 78P, 80P, 81P, 85P, 128, 214P, 255, 265, 272, 290, 305, 419, 441, 444, 479, 533P, 546P, 547P, 548P, 603, 615
Pharmacotherapy course, 587
Phenocopying, 73P
Phenol sulphotransferases, 413
Phenotype, 30, 161
Phenylephrine, 349
Phosphodiesterase inhibitors, 1
Phosphodiesterase isoenzymes, 1
Pirenzepine, 461
Piroxicam β-cyclodextrin, 546P
Plasma, 171
Plasma concentrations, 409P
Plasmid-mediated gene function, 554P
Plasminogen activators, 543
Platelet activating factor, 227
Platelet aggregation, 143, 485, 643
Platelet behaviour, 90P
Platelet function, 235
Platelets, 1
Polygalacturonate, 479
Polymorphism, 66P, 161, 331, 426, 540P, 549P
Polysomnography, 284
Portal blood flow, 517, 548P
Postmarketing surveillance, 400
Potassium, 373, 629
Pravastatin, 284
Praziquantel, 565
Prazosin, 538P
Precorneal residence time, 188
Pregnancy, 251, 664
Prescribing, 550P
Primaquine, 193
Probenecid, 533P, 609
Problem solving, 587, 591
Problem solving model, 581
Proguanil, 653
Promethazine, 551P
Propafenone, 553P
Propranolol, 73P, 114, 507, 629
Proprietary medicines, 451
Prostaglandin, 643
Protein binding, 609, 615
Protoscolicides, 565
Psychometric performance, 395
Psychomotor performance, 114, 272
Psychomotor responses, 14

Quinapril, 121
Quinidine, 265
Quinine, 305, 444
Quinolone derivative, 199

Rα-methylhistamine, 545P
Ranitidine, 543P
Rational drug describing, 575
Regulation, 324
Relative potency, 373
Relaxation, 366
Remoxipride, 615
Renal clearance, 20, 609
Renal disease, 62, 538P
Renal failure, 128
Renal function, 20, 21, 343, 539P, 615
Renal transports, 156
Resistance, 327
Respiratory burst, 485
Retrovirus-mediated gene expression, 554P
Reverse phase h.p.l.c., 78P
Rheumatoid arthritis, 261, 409, 603
Ridogrel, 541P
Ro 41-3696, 533P

Saccadic eye movements, 551P
Salbutamol, 413
Salicylic acid, 664
Saliva, 311, 431
Saturation, 20
Scalp hair, 199
Selegiline, 74P
Simvastatin, 284, 553P
Single dose, 386
Skeletal muscle, 629
Skin, 637
Sleep deprivation, 551P
Smooth muscle, 366
Sodium metabisulphite, 55
Spansule, 76P
Sparteine, 426
Sparteine metabolic ratio, 649
Spironolactone, 373
Splanchnic, 517
Stereoselective, 327
Stereoselective sulphation, 413
Stereoselectivity, 62
Stress, 553P
Stride length, 379
Stroke, 341
Subjective sleep assessment, 284
Sulphate, 609
Sulphate conjugation, 413
Superior mesenteric artery blood flow, 517
Superoxide ion, 89P, 485P
Surgical treatment, 565
Sustained release, 76P, 114
Systolic time intervals, 349

Tacrine hydrochloride, 82P
Teaching, 575
Terbutaline, 35, 629
Theophylline, 437, 657
Therapeutic consultation, 46
Thermogenesis, 629
Thioguanine, 75P
Thioperamide, 545P
Thromboxane, 235, 664
Thymidine analogue, 546P
Time-marker in hair, 199
Tissue plasminogen activator, 143
Tocainide, 437
Tolerability, 74P, 92P, 419
Tolrestat, 547P
Total clearance, 20
Toxicity, 219
Tramadol, 73P
Trandolapril, 128
Transfer, 591
Tricyclic antidepressants, 553P
Triglyceride, 40
Tubular transport, 20
Tucaresol, 419

UK Product Licence applications, 599
Undergraduate, 581, 587, 591
Urine, 171
Urine excretion, 409
VLDL, 91P
Vanoxerine, 308
Variability, 603
Vasculitis, 93P
Vasoactive intestinal polypeptide, 525
Vitamin K, 327

Warfarin, 327

Xamoterol, 35, 70P

Zidovudine, 534P